Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
Clinical Breast Cancer · 2026-11 · 26 (11) · 32-39
DOI: 10.1016/j.clbc.2026.09.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026-11. Verfasst von Hannah M Linden und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Estradiol, Antineoplastic Agents, Hormonal. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GE HealthCare Technologies Inc.
Abstract (Originalsprache)
PURPOSE: Many patients with ER-positive HER2-negative metastatic breast cancer (MBC) derive limited benefit from second line endocrine therapy. This study evaluated the impact of [18F]fluoroestradiol (FES) PET/CT on second line therapeutic decision-making. METHODS: Patients with progression of ER-positive HER2-negative MBC on first line endocrine therapy were prospectively enrolled in 17 U.S. centers to undergo [18F]FES PET/CT after standard-of-care (SoC) imaging. [18F]FES uptake in MBC lesions was evaluated. Treating oncologists completed questionnaires before and after [18F]FES PET/CT, detailing therapeutic decisions plus their confidence in the decisions. The primary endpoint was the proportion of patients whose therapeutic management changed after [18F]FES PET/CT. RESULTS: Between January 2023 and May 2024, 45 patients underwent [18F]FES PET/CT. Imaging results led to management changes in 17 patients (37.8%; 95% CI, 23.8%-53.5%). Twenty-five patients avoided further diagnostic testing, while 7 patients received additional tests. Oncologist's confidence in second line treatment decision increased on average from 6.6 before [18F]FES PET/CT to 8.6 afterward on a ten-point scale (P < .0001). In 25 patients (55.6%), lesions visible on SoC imaging were reported as "absent" (FES-negative) on [18F]FES PET/CT, suggesting potential loss or downregulation of ER that functionally binds estrogen. CONCLUSION: [18F]FES PET/CT altered therapeutic management in 37.8% of patients with MBC progressing on first line endocrine therapy and significantly increased oncologist's confidence in treatment selection. This imaging modality could help prevent unnecessary prolongation of ineffective endocrine therapy and delays in initiation of more effective options. Future studies should investigate potential outcome benefits after [18F]FES PET/CT-informed management changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology/Medical Oncology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: hmlinden@uw.edu.
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA.
- GE HealthCare, Pharmaceutical Diagnostics Research and Development, San Diego, CA.
- Medical Oncology, The Oncology Institute, CA.
- Department of Radiology, Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
- Margie Petersen Breast Center, Providence Saint John's Cancer Institute, Santa Monica, CA.
Förderung
- GE HealthCare Technologies Inc
Zitieren
APA
Linden, H. M., O'Brien, S. R., van de Ven, S. M., La Porte, P., Conti, P. S., Peddi, P. F., Mortimer, J. E., Brenin, C., Takalkar, A. M., McGuinness, J. E., Cheng, E., Rao, A., Peterson, L. M., Specht, J. M., Wong, T. Z., Buck, D. A., Brufsky, A. M., & Ulaner, G. A. (2026). Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy. Clinical Breast Cancer, 26(11), 32-39. https://doi.org/10.1016/j.clbc.2026.09.008
Vancouver
Linden HM, O'Brien SR, van de Ven SM, La Porte P, Conti PS, Peddi PF, et al. Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy. Clinical Breast Cancer. 2026;26(11):32-39. doi:10.1016/j.clbc.2026.09.008
BibTeX
@article{Linden2026,
author = {Linden, Hannah M and O'Brien, Sophia R and van de Ven, Stephanie M and La Porte, Paul and Conti, Peter S and Peddi, Parvin F and Mortimer, Joanne E and Brenin, Christiana and Takalkar, Amol M and McGuinness, Julia E and Cheng, Edgar and Rao, Amol and Peterson, Lanell M and Specht, Jennifer M and Wong, Terence Z and Buck, David A and Brufsky, Adam M and Ulaner, Gary A},
title = {Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {11},
pages = {32--39},
doi = {10.1016/j.clbc.2026.09.008}
}
EUVIMED